EANS-News: Agennix AG to Participate in 6th Annual International Partnering Conference BIO-Europe Spring® 2012

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, March 19,
2012 (euro adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced that the Company will participate in the 6th Annual
International Partnering Conference BIO-Europe Spring® 2012 to be
held March 19 - 21, 2012 in the RAI Convention Center, in Amsterdam,
The Netherlands. BIO-Europe Spring® is the springtime counterpart of
BIO-Europe® and continues the tradition of providing life science
companies with high caliber partnering opportunities across the life
science value chain. The Company will give a corporate presentation
on Wednesday, March 21, 2012 at 11:45, Level 1, room number E103.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company´s most
advanced program is talactoferrin, a first-in-class oral Dendritic
Cell Mediated Immunotherapy (DCMI). Talactoferrin is currently in
Phase III clinical trials in non-small cell lung cancer. Other
clinical development programs include RGB-286638, a multi-targeted
kinase inhibitor in Phase I testing for cancer, and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix´s registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. The achievement of
positive results in early stage clinical studies does not ensure that
later stage or large scale clinical studies will be successful. Even
if the results from our later stage trials with talactoferrin,
including the ongoing FORTIS-M trial in non-small cell lung cancer,
are considered positive, there can be no guarantee that they will be
sufficient to gain marketing approval in the United States or any
other country, and regulatory authorities may require additional
information, data and/or further pre-clinical or clinical studies to
support approval. In such event, there can be no guarantee that the
Company will have or be able to obtain the financial resources to
conduct any such additional studies or that such studies will yield
results sufficient for approval. Forward-looking statements speak
only as of the date on which they are made and Agennix undertakes no
obligation to update these forward-looking statements, even if new
information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Senior Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
regulated dealing/prime standard: Frankfurt
language: English